CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $101,219 | -37.9% | 2,490 | 0.0% | 0.02% | -37.5% |
| Q3 2022 | $163,000 | +7.9% | 2,490 | 0.0% | 0.03% | +6.7% |
| Q2 2022 | $151,000 | -26.3% | 2,490 | -23.9% | 0.03% | -16.7% |
| Q1 2022 | $205,000 | -17.3% | 3,270 | 0.0% | 0.04% | -2.7% |
| Q4 2021 | $248,000 | -32.2% | 3,270 | 0.0% | 0.04% | +23.3% |
| Q3 2021 | $366,000 | -30.8% | 3,270 | 0.0% | 0.03% | -30.2% |
| Q2 2021 | $529,000 | +32.9% | 3,270 | 0.0% | 0.04% | +43.3% |
| Q1 2021 | $398,000 | -89.6% | 3,270 | -86.9% | 0.03% | -88.8% |
| Q4 2020 | $3,823,000 | -54.5% | 24,970 | -78.2% | 0.27% | -65.2% |
| Q2 2020 | $8,407,000 | +1743.6% | 114,400 | +964.2% | 0.77% | +777.3% |
| Q1 2020 | $456,000 | – | 10,750 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |